Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
CRME is in the long-term down -82% below S&P in 6 years.
Description: Cardiome Pharma Corp., a biopharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies that enhance the life and health of patients. It offers BRINAVESS (vernakalant IV), for conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company?s pre-clinical research and development focuses on modulating cellular proteins (ion channels) that gate the movement of ions across the cell membrane to control various functions, including contraction of muscles, secretion from glands, and responses to foreign bodies and inflammation. It has operations in Canada, the United States, Switzerland, and the United Kingdom. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||ROE||ROI|
|Current Ratio||Quick Ratio||Long Term Debt/Equity||Debt Ratio|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||70 K||Cash From Investing Activities||-100 K||Cash From Operating Activities||-3.17 M||Gross Profit||4.27 M|
|Net Profit||-3.89 M||Operating Profit||-2.66 M||Total Assets||42.65 M||Total Current Assets||25.09 M|
|Total Current Liabilities||13.96 M||Total Debt||12 M||Total Liabilities||28.59 M||Total Revenue||5.5 M|
|High 52 week||4.71||Low 52 week||1.29||Last close||2.27||Last change||0%|
|RSI||50||Average true range||0.1||Beta||0.94||Volume||128.18 K|
|Simple moving average 20 days||-1.05%||Simple moving average 50 days||9.09%||Simple moving average 200 days||12.77%|
|Performance Week||-2.57%||Performance Month||-3.81%||Performance Quart||63.31%||Performance Half||52.35%|
|Performance Year||-31.63%||Performance Year-to-date||46.45%||Volatility daily||2.18%||Volatility weekly||4.88%|
|Volatility monthly||10%||Volatility yearly||34.63%||Relative Volume||275.87%||Average Volume||166.43 K|
|New High||New Low|
2018-05-15 16:11:26 | Cardiome: 1Q Earnings Snapshot
2018-05-15 16:00:00 | Correvio Reports First Quarter 2018 Financial Results
2018-05-15 08:40:00 | Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
2018-05-08 09:02:07 | Cardiome Pharma Corp TSE:COM: Should The Recent Earnings Drop Worry You?
2018-04-26 16:33:00 | Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
2018-04-12 07:00:00 | Cardiome Announces Fifteen Xydalba™ and Zevtera® Abstracts at ECCMID 2018
2018-04-09 14:15:00 | CRME: Cipher to Get Canadian Assets
2018-04-06 18:00:00 | Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
2018-04-02 08:00:00 | Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
2018-03-28 08:00:00 | Cardiome Announces Recent Insider Purchases
2018-03-22 08:05:00 | Cardiome Pharma Agrees to Sell Drug Portfolio, Analysts Target Price, Financial Review
2018-03-22 08:00:00 | Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
2018-03-19 10:30:00 | CRME: Cardiome’s 2017 Full Year Results
2018-03-13 19:49:33 | Cardiome reports 4Q loss
2018-03-13 16:00:00 | Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
2018-03-13 12:15:00 | Cardiome Pharma Corp. to Host Earnings Call
2018-03-06 14:11:09 | Cardiome Pharma Corp TSE:COM: Is Breakeven Near?
2018-02-26 16:11:09 | Are Cardiome Pharma Corp’s TSE:COM Interest Costs Too High?
2018-02-15 11:02:25 | Best TSX Growth Stocks
2018-02-08 08:00:00 | Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference
2018-02-05 11:00:00 | CRME: Initiating Coverage
2018-01-10 08:00:00 | Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit
2017-12-12 08:00:00 | Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
2017-11-20 08:00:00 | Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference
2017-11-16 05:14:39 | Cardiome reports 3Q loss
2017-11-14 16:01:00 | Cardiome Reports Third Quarter 2017 Financial Results
2017-11-14 11:00:00 | Cardiome Pharma Corp. to Host Earnings Call
2017-11-07 08:00:00 | Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14
2017-11-07 06:55:13 | What’s Installed For Cardiome Pharma Corp TSX:COM?
2017-11-02 08:00:00 | Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®
2017-10-30 08:00:00 | Cardiome Announces Commercial Launch of Xydalba™ in Three New European Geographies
2017-10-22 18:16:11 | Cardiome Pharma Corp TSX:COM: Time For A Financial Health Check
2017-09-06 08:30:00 | Cardiome, Pipeline Offers Opportunities Beyond Brinavess
2017-09-05 08:00:00 | Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference